-
Product Insights
NewPolycythemia Vera – Drugs In Development, 2024
Empower your strategies with our Polycythemia Vera – Drugs In Development, 2024 report and make more profitable business decisions. Polycythemia vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant, and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness, and excessive sweating. The risk of PV increases with age. Treatment includes alkylating agents. The Polycythemia Vera drugs in development market research report provide comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage...
-
Product Insights
NewInherited Neurodegenerative Diseases – Drugs In Development, 2024
Empower your strategies with our Inherited Neurodegenerative Diseases – Drugs In Development, 2024 report and make more profitable business decisions. Inherited neurodegenerative diseases are a group of disorders that affect the structure and function of neurons, leading to progressive loss of cognitive and motor abilities. Some of these diseases are caused by mutations in single genes, such as Huntington's disease, while others are influenced by multiple genetic and environmental factors, such as Alzheimer's disease and Parkinson's disease. The mechanisms of neuronal...
-
Product Insights
NewGastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2024
Empower your strategies with our Gastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2024 report and make more profitable business decisions. Gastrointestinal stromal tumors (GISTs) are tumors that occur in the gastrointestinal tract. GISTs belong to a group of cancers called soft tissue sarcomas. GISTs can be benign or malignant. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can be felt with the hand, nausea and vomiting, vomiting blood or having blood...
-
Product Insights
NewMesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2024
Empower your strategies with our Mesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2024 report and make more profitable business decisions. Mesenchymal tumors represent a heterogenous group of neoplasms that include malignant, intermediate malignancy, and benign entities. Sarcomas are extremely rare, accounting for only 1% of malignancies in adults and up to 10-15% of malignancies in the paediatric population. They are characterized by a global incidence of 30-50 cases per million person-years and show a wide anatomic distribution. Rarely,...
-
Product Insights
NewLung Adenocarcinoma – Drugs In Development, 2024
Empower your strategies with our Lung Adenocarcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Lung adenocarcinoma is the most common type of non-small cell lung cancer (NSCLC), accounting for a significant portion of lung cancer cases. It typically arises in the outer regions of the lungs and tends to develop in the smaller airways, known as bronchioles. Adenocarcinoma is characterized by cancerous cells that form glandular structures resembling the normal cells found lining the lungs. It...
-
Product Insights
NewCytomegalovirus (HHV-5) Infections – Drugs In Development, 2024
Empower your strategies with our Cytomegalovirus (HHV-5) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Cytomegalovirus (CMV) is virus in the herpes family, also called HHV-5. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, and hearing, neurological, and developmental problems. The predisposing factors are direct contact with an infected surface or individual, weakened immune system, and congenital factors. It may be diagnosed by blood or urine tests. The condition may be...
-
Product Insights
NewDiarrhea – Drugs In Development, 2024
Empower your strategies with our Diarrhea – Drugs In Development, 2024 report and make more profitable business decisions. Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle. The Diarrhea drugs in development market research report...
-
Product Insights
NewMedulloblastoma – Drugs In Development, 2024
Empower your strategies with our Medulloblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occurs in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting, and difficulty with walking and balance. Medulloblastoma can spread to...
-
Product Insights
NewPost-Polycythemia Vera Myelofibrosis (PPV-MF) – Drugs In Development, 2024
Empower your strategies with our Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Drugs In Development, 2024 report and make more profitable business decisions. Post-polycythemia vera myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, headaches, lack of concentration, and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant, and medications. The Post-Polycythemia...
-
Product Insights
NewPost-Essential Thrombocythemia Myelofibrosis (Post-ET MF) – Drugs In Development, 2024
Empower your strategies with our Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) – Drugs In Development, 2024 report and make more profitable business decisions. Post-essential thrombocythemia myelofibrosis (post-ET MF) is a rare, chronic blood disorder characterized by the progression of essential thrombocythemia (ET), a type of myeloproliferative neoplasm (MPN), to myelofibrosis (MF). It represents an advanced stage in the continuum of MPNs, involving abnormal production and functioning of blood cells in the bone marrow. Essential thrombocythemia is characterized by the overproduction of platelets...